ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2016
[LRRC3B is Downregulated in Non-small Cell Lung Cancer and Connected with Cell Proliferation and Invasion].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy.Frontiers in immunology · 2023Article
- Expression of Cyclin D1 gene in ovarian cancer and effect of silencing its expression on ovarian cancer cells based on the Oncomine database.Bioengineered · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLRRC3B expression is downregulated in many kinds of malignant tumors and it is regarded as tumor inhibition protein. However, the expression pattern and biological effect are still unclear in non-small cell lung cancer (NSCLC). Study of human cancer microarray showed LRRC3B was downregulated in breast cancer and colorectal cancer, which declares that LRRC3B takes part in tumor formation. This study is to investigate the expression of LRRC3B in lung cancer cell lines and the influence of LRRC3B during cell proliferation, invasion and cell cycle.
methodsThe expression of LRRC3B was detected through Western blot and Realtime RT-PCR. MTT assay, colony formation assay and matrigel invasion assay were performed to explore the effect of LRRC3B on cell proliferation, invasion and cell cycle. LRRC3B siRAN was transfected in lung cancer cell line H3255, and then the effect of LRRC3B on cell proliferation, invasion and cell cycle was analyzed.
resultsDuring 4 of 9 lung cancer cell lines, the expression of LRRC3B is downregulated compared with normal epithelial cells. Cell proliferation and invasion were inhibited in A549 and H460 after LRRC3B transfected. LRRC3B suppressed the progress of cell cycle and downregulated the expression of cyclin D1 and MMP9. The activity of proliferation and invasion was promoted after LRRC3B was knocked out in H3255.
conclusionsLRRC3B expression downreguated in lung cancer cell lines and LRRC3B could inhibit lung cancer cell proliferation, invasion and cell cycle progress. LRRC3B could be a new target for lung cancer therapy. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.